Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax

Am J Hematol. 2021 Mar 1;96(3):E65-E68. doi: 10.1002/ajh.26060. Epub 2020 Dec 14.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
  • Bridged Bicyclo Compounds, Heterocyclic / adverse effects*
  • Cytarabine / therapeutic use
  • Decitabine / administration & dosage
  • Female
  • Fluid Therapy
  • Humans
  • Hydroxyurea / therapeutic use
  • Incidence
  • Leukemia, Myeloid, Acute / complications
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myelomonocytic, Acute / complications
  • Leukemia, Myelomonocytic, Acute / drug therapy
  • Leukemia, Myelomonocytic, Acute / genetics
  • Leukocytosis / drug therapy
  • Leukocytosis / etiology
  • Male
  • Middle Aged
  • Phosphate-Binding Proteins / therapeutic use
  • Phosphorus / blood
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
  • Retrospective Studies
  • Sulfonamides / administration & dosage
  • Sulfonamides / adverse effects*
  • Tumor Lysis Syndrome / etiology*
  • Urate Oxidase / therapeutic use
  • Uric Acid / blood

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Phosphate-Binding Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • Cytarabine
  • rasburicase
  • Uric Acid
  • Phosphorus
  • Decitabine
  • Urate Oxidase
  • venetoclax
  • Hydroxyurea